Study of BH-30236 for leukemia and high-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia or high-risk myelodysplastic syndrome that has come back or not responded to previous treatments.
- You have had between 1 and 5 prior treatments for your condition.
- You are in reasonably good physical condition (able to do light activity).
- Your liver and kidney function are within acceptable ranges based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.